Pfizer to exit GSK joint venture after demerger


Share post:

US drugs giant Pfizer will exit its consumer healthcare joint venture with GlaxoSmithKline after the unit is spun off next month, the British drugmaker said Wednesday (June 1).

GSK will list the healthcare division on the London stock market on July 18 as it looks to concentrate on the pharmaceutical business, it said in a statement.

The London-listed firm currently owns a majority 68 percent of the unit, with Pfizer holding the remainder.

“Pfizer intends to exit its 32-percent ownership interest in Haleon in a disciplined manner, with the objective of maximising value for Pfizer shareholders,” GSK said.

Covid jab maker Pfizer is seeking to pursue its focus on “innovative medicines and vaccines”, it noted.

The unit, which will be named Haleon after the demerger, makes products including Sensodyne toothpaste, pain relief drug Panadol and cold treatment Theraflu.

For its part, Glaxo will “monetise its holding in Haleon in a disciplined manner to further strengthen the company’s balance sheet”, it added.

The company is pressing ahead with the demerger after rejecting a bid worth £50 billion for the unit from consumer goods titan Unilever.

The announcement Wednesday came one day after GSK snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion as part of the overhaul.

The Cambridge, Massachusetts-based group specialises in vaccines for diseases including meningitis, pneumonia and bloodstream infections.

Glaxo last month also bought US group Sierra Oncology, a specialist in medicines for rare forms of cancer, for $1.9 billion.

Chief executive Emma Walmsley is seeking to reshape Glaxo after she faced fierce investor criticism over the company’s delay in producing Covid jabs and treatments.


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...